Gloveless isolators don’t end interventions. Learn to assess intervention dependency in robotic aseptic filling and when glove ports are justified.
|Articles|June 2, 2014
- Pharmaceutical Technology-06-02-2014
- Volume 38
- Issue 6
Pharmaceutical Technology, June 2014 Issue (PDF)
Click the title above to open the Pharmaceutical Technology June 2014 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 12 years ago
Selecting a Specimen Holder for X-ray Powder Diffractionover 12 years ago
Single-Use Mixing System Improves Performanceover 12 years ago
Global Expansion Shapes Drug Oversightover 12 years ago
Regulating the Environmental Impact of Pharmaceuticalsover 12 years ago
Is a Sample Size of n=6 a 'Magic' Number?over 12 years ago
Centrifuges Increase Capacity and Flexibilityover 12 years ago
Hybrid Purifer Enhances Efficiencyover 12 years ago
Advances in Controlled-Release Drug Deliveryover 12 years ago
Brunei's Potential Pharmaceutical Market Growthover 12 years ago
Outsourcing No Longer Just for Cost-CuttingAdvertisement
Related to this article
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how the company’s product is worth the investment by protecting products and patients.
The FDA has shelved its National Priority Voucher pilot, leaving sponsors that built CMC and launch-readiness plans around 1- to 2-month reviews facing uncertain timelines.
Regulators will test pharma companies against their own internal AI policies. Jaenisch, Muraru, and Pandey explain how to build defensible, inspection-ready AI practices.
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how its connected technology can enhance anticounterfeiting and how data are handled within the product.
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.
Terry Katz, CEO and cofounder of ForgeStop Technology Corporation, explains the company’s CPHI Award-winning connected product technology and how it helps to combat drug counterfeiting.
FDA approved pimicotinib for TGCT based on a 56% response rate; its Project Orbis review signals tighter global launch planning for manufacturers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Signs Point to FDA Shelving Priority Voucher Pilot, Stalling Fast-Track Drug Reviews
2
Our Biggest Takeaways From AAPS PharmSci 360
3
PharmTech AI Pulse Check: Who's Accountable When a Vendor's AI Model Changes?
4
France Remains One of Europe’s Leading Biotech Funding Hubs
5